CADTH | Search

Current Filters

Showing 21 - 30 results of 3591

tildrakizumab (Ilumya ) (Last Updated: Aug 30, 2021)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Ilumya
Manufacturer:
Sun Pharma Canada
Submission Type:
Initial
Indications:

Treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Ivabradine (Lancora) for Heart Failure (Last Updated: Aug 8, 2019)

Heart failure is a condition characterized by reduced cardiac output occurring due to complications of cardiovascular disease. It is a leading cause of hospital admissions and has a poor prognosis...

Project Line:
Health Technology Review

Criteria for conducting Environmental Assessments in CADTH HTAs (Last Updated: Jun 5, 2019)

Environmental considerations are increasingly being recognized by decision-makers and policy-makers. Initiatives to “green” the delivery of health care and health technologies are becoming more common...

Project Line:
Health Technology Review
Project Status:
In Progress

tafamidis (Vyndaqel) (Last Updated: Mar 23, 2021)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Vyndaqel
Manufacturer:
Pfizer Canada
Submission Type:
Initial
Indications:

Treatment of adult patients with
cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or
hereditary, to reduce cardiovascular
mortality and cardiovascular-related hospitalization.

Download results as CSV